Leerink Partnrs upgraded shares of Adagene (NASDAQ:ADAG - Free Report) to a strong-buy rating in a report issued on Wednesday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Adagene's Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.68) EPS, FY2027 earnings at ($0.24) EPS, FY2028 earnings at ($0.35) EPS and FY2029 earnings at ($0.38) EPS.
Separately, Leerink Partners began coverage on shares of Adagene in a report on Wednesday, August 6th. They set an "outperform" rating and a $7.00 price objective on the stock.
Get Our Latest Stock Analysis on ADAG
Adagene Stock Performance
NASDAQ ADAG traded up $0.15 on Wednesday, hitting $2.32. The stock had a trading volume of 19,911 shares, compared to its average volume of 62,892. The business's fifty day moving average price is $1.95 and its 200 day moving average price is $1.81. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.30 and a quick ratio of 2.30. Adagene has a 52-week low of $1.33 and a 52-week high of $3.58.
Institutional Trading of Adagene
A number of hedge funds have recently bought and sold shares of the business. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Adagene during the 1st quarter worth approximately $29,000. Fifth Lane Capital LP purchased a new stake in shares of Adagene during the 4th quarter worth $54,000. Finally, Kamunting Street Capital Management L.P. purchased a new stake in Adagene in the fourth quarter valued at $251,000. Institutional investors and hedge funds own 9.51% of the company's stock.
About Adagene
(
Get Free Report)
Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.
See Also
Before you consider Adagene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adagene wasn't on the list.
While Adagene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access